TC
VRTX icon

Trilogy Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Trilogy Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,617
Closed -$1.68M – 346
2024
Q3 		$1.68M Buy
3,617
+748
+26% +$359K 0.08% 142
2024
Q2 		$1.34M Buy
2,869
+1,843
+180% +$800K 0.07% 155
2024
Q1 		$429K Buy
+1,026
New +$434K 0.02% 215
2018
Q4 		– Sell
-33
Closed -$6K – 562
2018
Q3 		$6K Hold
33
– – ﹤0.01% 389
2018
Q2 		$6K Hold
33
– – ﹤0.01% 358
2018
Q1 		$5K Buy
+33
New +$5.39K ﹤0.01% 319

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Trilogy Capital's VRTX Position: Q4 2024 in Review

Trilogy Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 3,617 shares — an estimated $1.68M sold.

Trilogy Capital first reported a position in VRTX in Q1 2018 and held it in 6 quarters. The position peaked at $1.68M in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Trilogy Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Trilogy Capital sold 3,617 Vertex Pharmaceuticals shares in Q4 2024, an estimated $1.68M.
  • Trilogy Capital first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • Trilogy Capital's Vertex Pharmaceuticals position peaked at $1.68M in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Trilogy Capital's 13F filing for Q4 2024, filed 27 Jan 2025.